Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 1/2 single-arm study of Promitil with radiotherapy in cisplatin-ineligible head and neck cancer
MOH_2026-09-09_017027Phase 2Recruiting
- Sponsor
- מחקר חוקר יזם
- Start
- Mar 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of Mitomycin-c lipidic prodrug in head and neck squamous cell carcinoma (HNSCC), sponsored by מחקר חוקר יזם. Primary endpoints: Short-term safety of Promitil with radiotherapy, Safe dose determination and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
Mitomycin-c lipidic prodrug
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on MOH_2026-09-09_017027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-09-09_017027.